Virtual forum – Young People and Adolescents with MPNs – Tue 21 Jan 2025

Registration is now open for the virtual forum – Young People and Adolescents with MPNs – scheduled for Tuesday 21st January 2025, from 6 to 7:30 PM (GMT).  The forum will feature presentations in French, Spanish, and English, utilizing AI-generated avatars to enhance the experience. We are thrilled to announce this virtual forum in collaboration…

Fundraising Team Christmas message 2024

As we approach the festive season, the MPN Voice Fundraising Team would like to extend our most heartfelt gratitude and warmest Christmas wishes to all our incredible fundraisers, supporters and community members. 2024 has been an extraordinary year of compassion, determination, and collective spirit.  Your incredible efforts have not just raised vital funds, but have…

MPN Voice 2024 round-up & Christmas message

Hello everyone It’s that time of year again for the round-up of the MPN Voice year.  We have had a very busy and successful 2024 and want to thank you all for your amazing support. The My MPN Voice App – the only MPN app you’ll ever need!  Launched earlier this year, the app will…

MAJIC-PV Study results

The MAJIC-PV Study is now completed and the results have been published Researchers wanted to find out how well Ruxolitinib worked compared with the best available therapy as a treatment for people with PV who were at risk of developing blood clots that could lead to a heart attack or stroke.  Specifically, the study looked…

In Conversation with… The Steering Committee Members of the MPN Advocates Network

In Conversation with The Steering Committee Members of the MPN Advocates Network.  The MPN AN was founded in 2013 by representatives from several MPN patient support groups as a way of creating and maintaining collaboration between these organizations and providing a platform for joint activity.  MPN AN is a leading international organization that operates for…

Update on the Shortage of Pegasys for Treating MPNs

We are very pleased to advise that NHS England has confirmed that Besremi is now available as a treatment option for specific people with MPNs – essential thrombocythaemia (ET), polycythaemia vera (PV) or myelofibrosis (MF) and for the duration of the Pegasys shortage. Doctors can now consider switching to the use of Besremi as an…